ClinicalTrials.gov
ClinicalTrials.gov Menu

Microarray Analysis of microRNA Expression in Basal Cell Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01498250
Recruitment Status : Completed
First Posted : December 23, 2011
Last Update Posted : October 16, 2012
Sponsor:
Information provided by (Responsible Party):
Michael Sand, Ruhr University of Bochum

Brief Summary:
Perturbations in microRNA (miRNA) expression profiles has been reported for a variety of cancers. This study will be an exploratory analysis of miRNA expression in basal cell carcinoma by miRNA expression profiling using microarrays.

Condition or disease
Basal Cell Carcinoma

Detailed Description:
Perturbations in the expression profiles of microRNAs (miRNAs) have been reported for a variety of different cancers. Basal cell carcinoma (BCC) of the skin has not been systematically evaluated regarding differentially expressed miRNAs. Patients with BCC are included in the study to perform an exploratory analysis by miRNA expression profiling using microarrays. Expression levels of miRNA candidates will be validated by TaqMan real-time quantitative polymerase chain reaction (RT-PCR).

Study Type : Observational
Actual Enrollment : 7 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Microarray Analysis of microRNA Expression in Basal Cell Carcinoma
Study Start Date : November 2011
Actual Primary Completion Date : December 2011
Actual Study Completion Date : December 2011

Group/Cohort
basal cell carcinoma
non-lesional skin



Biospecimen Retention:   Samples With DNA
basal cell carcinoma and non-lesional skin


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   1 Year and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with

Basal Cell Carcinoma

Criteria

Inclusion Criteria:

  • Basal Cell Carcinoma

Exclusion Criteria:

  • Other Skin Cancer than Basal Cell Carcinoma

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01498250


Locations
Germany
Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum
Bochum, NRW, Germany, 44791
Sponsors and Collaborators
Ruhr University of Bochum
Investigators
Study Director: Falk G Bechara, PD Dr. Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum
Study Chair: Peter Altmeyer, Prof. Dr. Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum
Principal Investigator: Michael Sand, Dr. Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum

Publications of Results:
Responsible Party: Michael Sand, Principal Investigator, Ruhr University of Bochum
ClinicalTrials.gov Identifier: NCT01498250     History of Changes
Other Study ID Numbers: microRNA6
First Posted: December 23, 2011    Key Record Dates
Last Update Posted: October 16, 2012
Last Verified: October 2012

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Basal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Basal Cell